LBA2: rEECur: Ifosfamide improved survival outcomes versus topotecan plus cyclophosphamide in patients with recurrent/refractory Ewing sarcoma

ASCO 2024

Multiple Myeloma (MM)

DREAMM-7: Belantamab mafodotin plus Vd improved survival and response rates in patients with RRMM, including those with poor prognostic features

ESMO 2024

Skin Cancer

CheckMate 067: Sustained survival benefit with nivolumab plus ipilimumab and nivolumab monotherapy versus ipilimumab in patients with advanced melanoma

ASCO 2024

Skin Cancer

COMBI-AD: Long-term outcomes favor dabrafenib plus trametinib versus placebo in patients with BRAF-mutated stage III melanoma

ASCO 2024

Genitourinary Cancer

OASIS: Rapid and deep responses to apalutamide plus ADT significantly improved survival in patients with mHSPC treated in real-world practice

Further Publications

Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703

J Clin Oncol

Holtan SG, Bolaños-Meade J, Al Malki MM, Wu J, Kitko CL, Reshef R, Rezvani AR, Shaffer BC, Solh MM, Yao JM, Runaas L, Elmariah H, Larkin KT, El Jurdi N, Gooptu M, Loren AW, Hall AC, Alousi AM, Jamy O, Clark W, Kean L, Bhatt AS, Perales MA, Applegate K, Efebera YA, Leifer E, Jones RJ, Horowitz MM, Mattila D, Saber W, Hamadani M, Martens MJ

doi: 10.1200/JCO.24.00921

Sarcoma

The survival disparity between children and adolescents and young adults (AYAs) with Ewing sarcoma in the Netherlands did not change since the 1990s despite improved survival: A population-based study

Eur J Cancer

Schulpen M, Haveman LM, van der Heijden L, Kaal SEJ, Bramer JAM, Fajardo RD, de Haan JJ, Hiemcke-Jiwa LS, Ter Horst SAJ, Jutte PC, Schreuder HWB, Tromp JM, van der Graaf WTA, van de Sande MAJ, Gelderblom H, Merks JHM, Karim-Kos HE

doi: 10.1016/j.ejca.2024.114209

ELCC 2025

Lung, Respiratory and Thoracic Cancer

MARIPOSA: First-line amivantamab plus lazertinib improves OS versus osimertinib in patients with EGFR-mutant advanced NSCLC

Lung, Respiratory and Thoracic Cancer

Survival outcome after surgery in patients with thymoma distant recurrence

J Thorac Oncol

Chiappetta M, Sassorossi C, Nachira D, Lococo F, Meacci E, Ruffini E, Guerrera F, Lyberis P, Aprile V, Lucchi M, Ambrogi MC, Bacchin D, Dell'Amore A, Marino C, Comacchio G, Roca G, Rea F, Margaritora S

doi: 10.1016/j.jtho.2024.04.004

ESMO 2024

Breast Cancer

ABIGAIL: Abemaciclib plus endocrine therapy improves ORR versus paclitaxel in patients with advanced HR+/HER2- breast cancer with aggressive disease criteria

Related content

DREAMM-7: Belantamab mafodotin plus Vd improved survival and response rates in patients with RRMM, including those with poor prognostic features

CheckMate 067: Sustained survival benefit with nivolumab plus ipilimumab and nivolumab monotherapy versus ipilimumab in patients with advanced melanoma

COMBI-AD: Long-term outcomes favor dabrafenib plus trametinib versus placebo in patients with BRAF-mutated stage III melanoma

OASIS: Rapid and deep responses to apalutamide plus ADT significantly improved survival in patients with mHSPC treated in real-world practice

Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703

The survival disparity between children and adolescents and young adults (AYAs) with Ewing sarcoma in the Netherlands did not change since the 1990s despite improved survival: A population-based study

MARIPOSA: First-line amivantamab plus lazertinib improves OS versus osimertinib in patients with EGFR-mutant advanced NSCLC

Survival outcome after surgery in patients with thymoma distant recurrence

ABIGAIL: Abemaciclib plus endocrine therapy improves ORR versus paclitaxel in patients with advanced HR+/HER2- breast cancer with aggressive disease criteria